News Focus
News Focus
icon url

tdtcal

07/31/16 10:36 PM

#71892 RE: dadofmarcmax #71889

Nice summary.
icon url

neiu

07/31/16 10:42 PM

#71895 RE: dadofmarcmax #71889

finally gave up on the "intellectual" discussions on the ymb? Welcome to the ihub board. Look forward to hearing another voice
icon url

sage4

08/01/16 1:33 AM

#71910 RE: dadofmarcmax #71889

Welcome on board, doc!

Thanks. I certainly disturbed by unexpected(by many) drop in share price.
icon url

kld2

08/01/16 6:24 AM

#71921 RE: dadofmarcmax #71889

glad to have you, doc. I have read your posts on epilepsy. Hope you stick around and contribute.
icon url

twiz0019

08/01/16 7:17 AM

#71923 RE: dadofmarcmax #71889

Good post dado....however, is big pharma willing to partner with Anavex to fund that next trial...THAT is the big question!.
icon url

blu_1

08/01/16 9:00 AM

#71937 RE: dadofmarcmax #71889

Do the patients with MCI also have mild Alzheimers? Orrrr, extra mild Alzheimers? What differentiates them with the patients in the mild-moderate group that have mild symptoms?
icon url

sokol

08/01/16 9:05 AM

#71939 RE: dadofmarcmax #71889

AVXL 2-73 is better than Aricept if this clinical trial only shows that there is no significantly statistical cognitive decline patients in the trial at 52 weeks or even if there is a decline in MMSE scoring of less than 3.

AVXL 2-73 is also better than Aricept if it shows and continues to show this:

'Therapeutic Response Unexpected'. A sample of verbatim terms reported include:
Improved Engagement with Family/Friends
Improvement in Mood
Increased Independent Activity
Feeling Happier
Improved Alertness
Better Coordination
Better Coping

Thank you for posting.